Coherus Oncology (CHRS) EBITDA Margin Growth (3y) (2016 - 2026)
Powered by 
Analysis
Coherus Oncology (CHRS) EBITDA Margin Growth (3y) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | -347.00 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -15,844.00 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | -377.00 |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | -204.00 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 7,045.00 |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -1,934.00 |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 9,003.00 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -2,825.00 |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -2.41 Mn |
| 10 | Coherus Oncology | 209.00 Mn | 103.70 Mn | 10.07 Mn | -16,715.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -16,715.00 |
| Mar 31, 2026 | -8,481.00 |
| Dec 31, 2025 | -24,636.00 |
| Sep 30, 2025 | -20,603.00 |
| Jun 30, 2025 | -37,042.00 |
| Mar 31, 2025 | -46,329.00 |
| Dec 31, 2024 | -53,297.00 |
| Sep 30, 2024 | -73,448.00 |
| Jun 30, 2024 | -35,730.00 |
| Mar 31, 2024 | -273,549.00 |
| Dec 31, 2023 | -9,016.00 |
| Sep 30, 2023 | -7,261.00 |
| Jun 30, 2023 | -10,697.00 |
| Mar 31, 2023 | -24,403.00 |
| Dec 31, 2022 | -14,990.00 |
| Sep 30, 2022 | -22,352.00 |
| Jun 30, 2022 | -10,612.00 |
| Mar 31, 2022 | -8,988.00 |
| Jun 30, 2020 | 409,371.00 |
| Mar 31, 2020 | 4.50 Mn |